Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia - ScienceDirect
Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia - ScienceDirect
Plasmacytoid dendritic cells proliferation associated with acute myeloid leukemia: phenotype profile and mutation landscape | Haematologica
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia - ScienceDirect
Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches | SpringerLink
Frontiers | Bispecific antibody-targeted T-cell therapy for acute myeloid leukemia
Microenvironment and drug resistance in acute myeloid leukemia: Do we know enough? - Ganesan - 2022 - International Journal of Cancer - Wiley Online Library
Return of gemtuzumab ozogamicin in acute myeloid leukemia—Is it for everyone with CD33+ disease? - Boddu - 2018 - ADVANCES IN CELL AND GENE THERAPY - Wiley Online Library
PROFILE OF CD150 EXPRESSION IN BONE MARROW CELLS OF PATIENTS WITH ACUTE MYELOID LEUKEMIA | Experimental oncology
Cytokines increase engraftment of human acute myeloid leukemia cells in immunocompromised mice but not engraftment of human myelodysplastic syndrome cells | Haematologica
Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia | Science Translational Medicine
Cancers | Free Full-Text | A Focus on Intermediate-Risk Acute Myeloid Leukemia: Sub-Classification Updates and Therapeutic Challenges
Frontiers | Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
Gemtuzumab Ozogamicin (GO) Inclusion to Induction Chemotherapy Eliminates Leukemic Initiating Cells and Significantly Improves Survival in Mouse Models of Acute Myeloid Leukemia - ScienceDirect
C-Type Lectin-Like Molecule-1 as a Biomarker for Diagnosis and Prognosis in Acute Myeloid Leukemia: A Preliminary Study
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option | Oncogene
Expression of CD33 on malignant and normal myeloid cells. (a) CD33 is... | Download Scientific Diagram
![IJMS | Free Full-Text | Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative Induces Differentiation-Coupled Apoptosis of Immature Myeloid Cells Such as Acute Myeloid Leukemia and Myeloid-Derived Suppressor Cells](https://pub.mdpi-res.com/ijms/ijms-21-05135/article_deploy/html/images/ijms-21-05135-ag.png?1596074383 "IJMS | Free Full-Text | Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative Induces Differentiation-Coupled Apoptosis of Immature Myeloid Cells Such as Acute Myeloid Leukemia and Myeloid-Derived Suppressor Cells")
IJMS | Free Full-Text | Imidazo[1,2-b]pyrazole-7-Carboxamide Derivative Induces Differentiation-Coupled Apoptosis of Immature Myeloid Cells Such as Acute Myeloid Leukemia and Myeloid-Derived Suppressor Cells
Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1 - Zhou - 2019 - Cytometry Part B: Clinical Cytometry - Wiley Online Library
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia | PLOS ONE
Extinguishing the Embers: Targeting AML Metabolism: Trends in Molecular Medicine
IJMS | Free Full-Text | Flow Cytometric Identification of Hematopoietic and Leukemic Blast Cells for Tailored Clinical Follow-Up of Acute Myeloid Leukemia
Cancers | Free Full-Text | Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
